Using Biomarkers to Predict TB Treatment Duration (Predict TB): a Prospective, Randomized, Noninferiority, Treatment Shortening Clinical Trial

Overview

Journal Gates Open Res

Specialties Health Services
Public Health

Date 2018 Mar 13

PMID 29528048

Citations 18

Authors

Ray Y Chen

Laura E Via

Lori E Dodd

Gerhard Walzl

Stephanus T Malherbe

Andre G Loxton

Rodney Dawson

Robert J Wilkinson

Friedrich Thienemann

Michele Tameris

Mark Hatherill

Andreas H Diacon

Xin Liu

Jin Xing

Xiaowei Jin

Zhenya Ma

Shouguo Pan

Guolong Zhang

Qian Gao

Qi Jiang

Hong Zhu

Lili Liang

Hongfei Duan

Taeksun Song

David Alland

Michael Tartakovsky

Alex Rosenthal

Christopher Whalen

Michael Duvenhage

Ying Cai

Lisa C Goldfeder

Kriti Arora

Bronwyn Smith

Jill Winter

Clifton E Barry Iii

Affiliations

Soon will be listed here.

Abstract

Trial Registration: NCT02821832.

Citing Articles

PET/CT guided tuberculosis treatment shortening: a randomized trial.

Malherbe S, Chen R, Yu X, Smith B, Liu X, Gao J medRxiv. 2025; .

PMID: 39802795 PMC: 11722446. DOI: 10.1101/2024.10.03.24314723.

Comparing gene expression profiles of adults with isolated spinal tuberculosis to disseminated spinal tuberculosis identified by FDG-PET/CT at time of diagnosis, 6- and 12-months follow-up: classifying clinical stages of spinal tuberculosis and....

Scherer J, Mukasa S, Wolmarans K, Guler R, Kotze T, Song T J Orthop Surg Res. 2024; 19(1):376.

PMID: 38918806 PMC: 11202394. DOI: 10.1186/s13018-024-04840-7.

Multi-level tuberculosis of the spine identified by 18 F-FDG-PET/CT and concomitant urogenital tuberculosis: a case report from the spinal TB X cohort.

Scherer J, Mukasa S, Wolmarans K, Guler R, Kotze T, Song T Infection. 2024; 52(6):2507-2519.

PMID: 38896371 PMC: 11621135. DOI: 10.1007/s15010-024-02327-5.

Subclinical tuberculosis: a meta-analysis of prevalence and scoping review of definitions, prevalence and clinical characteristics.

Teo A, MacLean E, Fox G Eur Respir Rev. 2024; 33(172).

PMID: 38719737 PMC: 11078153. DOI: 10.1183/16000617.0208-2023.

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.

Dartois V, Dick T Nat Rev Drug Discov. 2024; 23(5):381-403.

PMID: 38418662 PMC: 11078618. DOI: 10.1038/s41573-024-00897-5.

References

Friedrich S, Rachow A, Saathoff E, Singh K, Mangu C, Dawson R . Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2014; 1(6):462-70. DOI: 10.1016/S2213-2600(13)70119-X. View

Kurbatova E, Cegielski J, Lienhardt C, Akksilp R, Bayona J, Becerra M . Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015; 3(3):201-9. PMC: 4401426. DOI: 10.1016/S2213-2600(15)00036-3. View

Hanrahan C, Theron G, Bassett J, Dheda K, Scott L, Stevens W . Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014; 189(11):1426-34. PMC: 4098085. DOI: 10.1164/rccm.201312-2140OC. View

Coleman M, Maiello P, Tomko J, Frye L, Fillmore D, Janssen C . Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2014; 82(6):2400-4. PMC: 4019174. DOI: 10.1128/IAI.01599-13. View

Weiner M, Prihoda T, Burman W, Johnson J, Goldberg S, Padayatchi N . Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol. 2010; 48(12):4370-6. PMC: 3008491. DOI: 10.1128/JCM.00757-10. View

Chen R, Dodd L, Lee M, Paripati P, Hammoud D, Mountz J . PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. 2014; 6(265):265ra166. PMC: 5567784. DOI: 10.1126/scitranslmed.3009501. View

Malherbe S, Shenai S, Ronacher K, Loxton A, Dolganov G, Kriel M . Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med. 2016; 22(10):1094-1100. PMC: 5053881. DOI: 10.1038/nm.4177. View

Phillips P, Fielding K, Nunn A . An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One. 2013; 8(5):e63840. PMC: 3648512. DOI: 10.1371/journal.pone.0063840. View

Zierski M, BEK E, Long M, Snider Jr D . Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1980; 122(6):879-89. DOI: 10.1164/arrd.1980.122.6.879. View

10.

Phillips P, Mendel C, Burger D, Crook A, Crook A, Nunn A . Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med. 2016; 14:19. PMC: 4743210. DOI: 10.1186/s12916-016-0565-y. View

11.

Horne D, Royce S, Gooze L, Narita M, Hopewell P, Nahid P . Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(6):387-94. PMC: 3046810. DOI: 10.1016/S1473-3099(10)70071-2. View

12.

Podewils L, Gler M, Quelapio M, Chen M . Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes. PLoS One. 2013; 8(7):e70064. PMC: 3726487. DOI: 10.1371/journal.pone.0070064. View

13.

Lew W, Pai M, Oxlade O, Martin D, Menzies D . Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008; 149(2):123-34. DOI: 10.7326/0003-4819-149-2-200807150-00008. View

14.

Pasipanodya J, McIlleron H, Burger A, Wash P, Smith P, Gumbo T . Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013; 208(9):1464-73. PMC: 3789573. DOI: 10.1093/infdis/jit352. View

15.

Boehme C, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F . Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363(11):1005-15. PMC: 2947799. DOI: 10.1056/NEJMoa0907847. View

16.

Wallis R, Kim P, Cole S, Hanna D, Andrade B, Maeurer M . Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis. 2013; 13(4):362-72. DOI: 10.1016/S1473-3099(13)70034-3. View

17.

Pasipanodya J, Srivastava S, Gumbo T . Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012; 55(2):169-77. PMC: 3491771. DOI: 10.1093/cid/cis353. View

18.

Yew W, Chan C, Chau C, Tam C, Leung C, Wong P . Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000; 117(3):744-51. DOI: 10.1378/chest.117.3.744. View

19.

Hesseling A, Walzl G, Enarson D, Carroll N, Duncan K, Lukey P . Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis. 2010; 14(5):560-70. View

20.

. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1989; 139(4):871-6. DOI: 10.1164/ajrccm/139.4.871. View